Introduction
tendency in chronic haemodialysis patients. Finally, preventative measures for these coagulation defects An increased thrombotic tendency is an important will be discussed. cause of complications in chronic haemodialysis patients, leading not only to possibly fatal complications like ischaemic heart disease or stroke, but also to thrombosis of the vascular access [1] . This latter Normal haemostasis and fibrinolysis complication remains the main problem in vascular access for haemodialysis, particularly in polytetrafluo-Normal haemostatic responses are initiated by damage roethylene (PTFE) grafts. It accounts for considerable of the vessel wall with exposure of subendothelial morbidity and mortality with an estimated annual cost structures to flowing blood and results in the formation of close to $1 billion in the United States. Moreover, of a solid haemostatic plug. The first step of this vascular access complications mainly consisting of haemostatic response involves platelet adherence to thrombotic events are responsible for 17-25% of all the subendothelium [15] [16] [17] . The number of platelets hospitalizations in dialysis patients [2] [3] [4] .
available for this process is determined by platelet In most cases thrombosis is associated with low count. It is, however, even more dependent on red access blood flow [5] [6] [7] . The most important reason blood cell-mediated transport of circulating platelets for a decreasing access blood flow is intimal hyperplasia towards the vessel wall [17] [18] [19] . The adhesion of formation at the venous anastomosis or in the outflow platelets to the site of injury is initially mediated by tract of the graft [8-13]. However, not all decreases in interactions between specific platelet receptors (e.g. access blood flow are related to intimal hyperplasia or glycoprotein Ib) and adhesive proteins in or deposited stenosis formation. Other causes for low access flow on the subendothelium (e.g. von Willebrand factor, leading to access thrombosis have been proposed vWF ) [20] [21] [22] . The quality of the platelet adhesion ( Table 1) . Hypotension, hypovolaemia, or external depends strongly on subsequent platelet activation. compression may be involved in these non-stenotic Platelet activation is initiated by stimuli originating thrombotic events [14] . Also, there has been a growing from the vessel wall but is sustained by products appreciation of the role of hypercoagulability states released from activated platelets themselves, for found in these patients.
example thromboxane and adenosine diphosphate This review will discuss coagulability abnormalities (ADP) [22] . Platelet activation leads to expression of in relation to haemodialysis access thrombosis. First, additional receptors on platelet membranes which supan outline will be given regarding normal haemostatic port platelet interaction with subendothelium (e.g. and fibrinolytic responses. Subsequently, we will focus glycoprotein IIb/IIIa) [22] [23] [24] [25] . Most importantly, however, these receptors mediate platelet-platelet gen. Thrombin proteolytically converts fibrinogen to insoluble fibrin, which in its turn activates factor XIII that causes cross-linking of fibrin fibres [26 ] . With Correspondence and offprint requests to: Johannes H. M. Smits, collagen, thrombin is also a main stimulus of platelet stabilize platelet aggregates and other cellular elements bleeding tendency, other circumstances may actually lead to an increase in thrombotic complications. First in a shear stress-resistant network. Pathological thrombin formation is prevented by natural anticoagulant of all, although some studies suggest a decreased membrane expression or an abnormal activation of systems, of which antithrombin III and the vitamin K-dependent protein C systems are the most important platelet receptors (glycoprotein Ib and IIb/IIIa) [30, 31] , an increase in platelet receptor number may ones. In addition to these anticoagulant systems, the fibrinolytic system generates plasmin by the action of be related to frequent access obstruction [32] . Also, haemodialysis is thought to activate platelets by adhertissue plasminogen activator on plasminogen. Plasmin dissolves the fibrin clot and thereby prevents patholo-ence to the extracorporeal circuit [33, 34] . In addition to extracorporeal activation, high shear stress and gical thrombus formation. Thus, normal haemostatic responses require both coagulation-and platelet-turbulence in the vascular access may be responsible for further platelet activation [35, 36 ] . Another condidependent processes.
In haemodialysis patients, complex coagulation tion favouring vascular access clotting is that the artificial surface of the PTFE graft, and to a lesser abnormalities occur, ranging from bleeding to thrombosis [1, 27] . On the one hand, the enhanced bleeding extent the native arteriovenous (AV ) fistula, promotes the adhesion of fibrinogen [37, 38] . Serum fibrinogen, tendency in these patients is primarily based on functional platelet abnormalities and defective adhesion to which is increased in haemodialysis patients, adheres
to ( Table 2) .
derived growth factor (PDGF ), for example)) which lead to or enhance intimal hyperplasia in the vascular Platelet abnormalities access and thereby reduce blood flow through the access, which allows other activated or non-activated Platelet abnormalities are common in patients on platelets to aggregate more easily. This creates, deshaemodialysis. Paradoxically, most studies on platelet pite a bleeding tendency, a favourable situation for abnormalities in haemodialysis patients have focused thrombosis. on adhesion defects leading to an increased bleeding tendency. So, first of all, do these platelets actually play a role in the thrombotic tendency seen in patients Plasma factor abnormalities on haemodialysis? In other words, are there abnormal Uraemic subjects have higher levels of fibrinogen while circumstances leading to an increase of thromboemat the same time thrombin formation is increased bolic complications in a setting of dysfunctional plate- [41, 42] . Song et al. [43] showed that a high plasma lets? Indeed, there are indications that this is the case.
fibrinogen level is an independent risk factor for vascuAlthough platelet abnormalities exist which favour a lar access failure in haemodialysis patients. In addition, levels of antithrombin III may be decreased and Table 2 . Factors contributing to an increased thrombotic tendency antithrombin III activity may be reduced [44, 45] . The in patients on chronic haemodialysis subsequent increase of in vivo fibrinogen-fibrin transformation is reflected by increased fibrinopeptide A Others have shown that antiphospholipid anti-reviewed by the Antiplatelet Trialists' Collaboration bodies are predictive of vascular access thrombosis Group [66 ] . Outcomes of nine placebo-controlled, [45, [47] [48] [49] . These antibodies include lupus anticoagu-randomized trials showed an occlusion rate of 17% in lant (LA), anticardiolipin antibodies (ACA), and anti-the antiplatelet groups vs 39% in the control groups. phosphatidyl serine antibodies. Higher titres of both Antiplatelet regimens consisted of ticlopidine (five stud-ACA and LA antibodies have been demonstrated in ies), aspirin (two studies), and sulphinpyrazone (two patients with ESRD than in the general population studies). Unfortunately, most of the evaluated studies [48, 50, 51] . Elevated LA antibody titres are present in were conducted in the late 1970s and the beginning of up to one-third of haemodialysis patients [48] . Elevated the 1980s. At that time some of the achievements in ACA antibody titres have been found in 0-29% of modern dialysis were not yet available, and dialysis them [48, 52, 53] , with a greater prevalence in patients populations differed from those of today. Moreover, with AV grafts (22%) than with native AV fistulae these studies had only a short follow-up (mean 2 (6%) [47] . However, the association between elevated months). Finally, the analysis report was difficult to ACA antibody titres and increased access thrombosis interpret in terms of excess bleeding due to antiplateis not fully established yet. While several studies found let therapy. no association [48,52,54], Prakash et al. [47] demonOnly one randomized, placebo-controlled clinical strated in a retrospective study a 3.7 times increased trial comparing access thrombosis frequency in patients risk of recurrent thrombosis in patients with PTFE treated with antiplatelet therapy (dipyridamole 75 mg grafts having elevated ACA antibody titres. The latter orally three times a day, or aspirin 325 mg orally daily) finding was recently confirmed in a prospective study: was conducted in the last decade. Surprisingly, dipyridthe survival time of PTFE grafts in patients with amole alone, which is considered as a relatively weak elevated titres was significantly shorter than in patients platelet inhibitor, had the best outcome, while patients with normal titres. Interestingly, this difference was on aspirin had the highest frequency of thrombosis, not found in patients with native AV fistula [53] . even higher than with placebo or the combination of Hyperhomocysteinaemia is an independent risk dipyridamole and aspirin [67] . The results of this study factor for recurrent and early-onset venous thrombosis became more understandable after the authors conin patients with normal renal function [55] [56] [57] . Fasting ducted a series of in vitro experiments using vascular homocysteine levels have been shown to be elevated in smooth-muscle cells [68, 69] . They could show that patients with ESRD [58] and may contribute to atheroaspirin potentiated PDGF-induced vascular smoothsclerosis and subsequent cardiovascular events in muscle cell proliferation by shunting arachidonic acid haemodialysis patients [59, 60] . The underlying mechanism by which hyperhomocysteinaemia provokes from cyclo-oxygenase into lipoxygenase pathways. On thrombosis is uncertain. It may involve a change in the other hand, dipyridamole profoundly inhibited factor V and protein C complex activity as well as PDGF-and bFGF-induced vascular smooth-muscle effects on platelet function [56, 61, 62] .
cell proliferation. This suggests that the observed direct Studies on the association of homocysteine and effect of aspirin and dipyridamole on vascular smoothaccess thrombosis are limited and the results are con-muscle cell proliferation (rather than the antiplatelet troversial. In a retrospective study by Manns et al. effect) is a better explanation for the reported clinical [52] no association between homocysteine level and efficiency of dipyridamole. Gastrointestinal bleeding access thrombosis was found. Two recent prospective occurred in 16% of the treated patients vs 8% in the studies showed conflicting results. Shemin et al.
[63] placebo group. Unfortunately, no anatomical or funcdemonstrated a 4% increase in the risk of access tional data (e.g. vascular access flow) was collected in thrombosis with each 1 mmol/l increase of plasma the randomized trial [67] . This could have provided homocysteine concentration for both AV fistulae and further in vivo evidence for the experimental in vitro grafts. Similarly, Ducloux et al. [64] suggested that data. hyperhomocysteinaemia is a risk factor for vascular Finally, Windus et al. [70] showed that aspirin and access thrombosis. However, such an association could ticlopidine both reduced dialysis-associated platelet not be demonstrated in a population of 96 patients deposition in PTFE grafts, although they did not with only native AV fistulae. The patients with the completely prevent it. lowest levels even appeared to have an increased mortality risk [65] . These conflicting differences in outcome may be related to the type of fistula, to the length of Oral anticoagulation follow-up, and to other variables. Obviously, longCurrent opinion on the use of systemic anticoagulant term prospective studies with serial, instead of therapy to improve access patency is primarily based occasional, determinations of plasma homocysteine are on personal belief, rather than on evidence. Not surneeded to solve this issue.
prisingly, the reason is that systematic data on this subject are very limited. Interestingly, despite the lack
Therapeutic considerations
of consensus, nephrologists do not refrain from prescribing anticoagulants. As a consequence numerous Antiplatelet therapy different anticoagulant strategies exist from centre to centre as to patient selection, dosing scheme, and The usefulness of antiplatelet therapy for the maintenance of internal haemodialysis access devices was treatment duration.
In 
